These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. Ong G; Goh KT; Ma S; Chew SK J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282 [TBL] [Abstract][Full Text] [Related]
25. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R; Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189 [TBL] [Abstract][Full Text] [Related]
26. Commentary: Mumps vaccines: do we need a new one? Plotkin SA Pediatr Infect Dis J; 2013 Apr; 32(4):381-2. PubMed ID: 23552675 [No Abstract] [Full Text] [Related]
27. Increasing incidence of mumps in Scotland: options for reducing transmission. Donaghy M; Cameron JC; Friederichs V J Clin Virol; 2006 Feb; 35(2):121-9. PubMed ID: 16289903 [TBL] [Abstract][Full Text] [Related]
32. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia. Jaber SM Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596 [TBL] [Abstract][Full Text] [Related]
33. Mumps vaccine performance among university students during a mumps outbreak. Cortese MM; Jordan HT; Curns AT; Quinlan PA; Ens KA; Denning PM; Dayan GH Clin Infect Dis; 2008 Apr; 46(8):1172-80. PubMed ID: 18444852 [TBL] [Abstract][Full Text] [Related]
34. [Epidemic parotiditis, a reportable disease]. Boverhoff JC; Baart JA Ned Tijdschr Tandheelkd; 2013 Jan; 120(1):22-6. PubMed ID: 23413587 [TBL] [Abstract][Full Text] [Related]
35. Mumps vaccines: do we need a new one? Rubin S; Beeler J Pediatr Infect Dis J; 2013 Oct; 32(10):1156-7. PubMed ID: 24067559 [No Abstract] [Full Text] [Related]
36. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. Bitsko RH; Cortese MM; Dayan GH; Rota PA; Lowe L; Iversen SC; Bellini WJ J Clin Microbiol; 2008 Mar; 46(3):1101-3. PubMed ID: 18184850 [TBL] [Abstract][Full Text] [Related]
37. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants. Yerkovich ST; Rowe J; Richmond P; Suriyaarachchi D; Heaton T; Hollams E; Ladyman C; Serralha M; Sadowska A; Loh R; Wesselingh SL; Sly PD; Holt PG Vaccine; 2007 Feb; 25(10):1764-70. PubMed ID: 17224218 [TBL] [Abstract][Full Text] [Related]
38. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R; Rahman MM; Hassan Z; Hassan MS Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626 [TBL] [Abstract][Full Text] [Related]
39. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related]
40. Mumps in a boarding school: description of an outbreak and control measures. Mackenzie DG; Craig G; Hallam NF; Moore J; Stevenson J Br J Gen Pract; 2006 Jul; 56(528):526-9. PubMed ID: 16834879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]